The following is a summary of “Prognostic Significance of Preoperative NLR or PLR and PASS Score Combinations in Pheochromocytoma and Paraganglioma,” published in the December 2024 issue of Endocrinology by Çavdar et al.
The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are emerging prognostic markers for pheochromocytomas and paragangliomas (PPGLs). Still, their combined value with the Pheochromocytoma and Paraganglioma Scoring System (PASS) score remains unclear.
Researchers conducted a retrospective study to assess the prognostic value of NLR and PLR combined with the PASS score in people with PPGLs.
They analyzed data from 74 people with histologically confirmed PPGLs. Poor prognosis was defined by metastasis or disease-specific mortality. The prognostic significance of the PASS score combined with NLR or PLR was evaluated using the Receiver Operating Characteristic Curve (ROC), univariate, and multivariate regression analysis.
The results showed that poor prognosis was associated with NLR > 3.43 (Area Under Curve [AUC] = 0.761; 70% sensitivity, 82.8% specificity, 38.9% positive predictive value [PPV], and 94.7% negative predictive value [NPV]) and PLR > 193.12 (AUC = 0.738; 70% sensitivity, 76.2% specificity, 30% PPV, and 94% NPV). The combination of PASS score ≥6 and NLR > 3.43 predicted poor prognosis (OR: 125; 95% CI: 6.25–∞; P=0.001), as did PASS score ≥6 and PLR > 193.12 (OR: 28.57; 95% CI: 3–250; P=0.003).
They concluded that combining NLR and PLR with the PASS score can improve the preoperative prognosis and management of people with PPGLs.
Source: onlinelibrary.wiley.com/doi/full/10.1111/cen.15192
The post PASS Score and Inflammatory Markers NLR, PLR in Prognosis Prediction first appeared on Physician's Weekly.